Clinical trial
Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients…
NCT00238901 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00238901 |
|---|---|
| Title | Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation |
| Official title | Efficacy and Safety of Basiliximab in HCV+ Patients Undergoing Liver Transplantation, as Compared With Steroids, Both Given in Combination With Cyclosporine and Mycophenolate Mofetil (MMF) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Liver Transplant |
| Intervention type | Drug |
| Interventions | Basiliximab |
| Enrollment | 194 |
| Start date | Dec 1, 2002 |
| Primary completion | Jul 1, 2005 |
| First posted | Oct 14, 2005 |
| Last update posted | Sep 1, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: